Please check your internet connection and try again.
# Hyoscine Butylbromide
## Overview
Hyoscine butylbromide (scopolamine butylbromide) is a quaternary ammonium antispasmodic agent. Unlike tertiary amines (e.g., scopolamine hydrobromide), it does not cross the blood-brain barrier and therefore lacks significant central anticholinergic effects.
## Primary Indications
* Symptomatic relief of gastrointestinal, biliary, and genitourinary smooth muscle spasms.
* Palliative setting: Management of "death rattle" (secretions in the terminal phase).
## Adult Dosing
* **Oral (Spasm):** 10 mg to 20 mg three to four times daily. Maximum: 100 mg/day.
* **Parenteral (IM/IV/SC):** 20 mg as a single dose; may be repeated as needed. Maximum: 100 mg/day.
* **Palliative Care Injection:** 10–20 mg SC q4h PRN or 20–60 mg per 24 hours via continuous subcutaneous infusion (CSCI).
## Pediatric Dosing
* **Children 6–12 years:** 10 mg oral up to three times daily.
* **Data Note:** Use in children under 6 years is generally off-label or not recommended; consult local pediatric formulary for specific weight-based institutional protocols.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No standard titration guidelines exist, but use with caution due to decreased clearance; consider starting at the lower end of the dosing range.
* **Elderly:** Increased susceptibility to anticholinergic side effects (e.g., urinary retention, constipation).
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Megacolon.
* Paralytic ileus or intestinal obstruction.
* Narrow-angle glaucoma.
* Tachycardia/Thyrotoxicosis.
* Prostatic hypertrophy with urinary retention.
## Adverse Effects
* **Common:** Dry mouth, visual accommodation disturbances, tachycardia, constipation.
* **Serious:** Anaphylaxis (rare), urinary retention, increased intraocular pressure, injection site reactions.
## Key Drug Interactions
* **Anticholinergics:** Additive effects (increased risk of dry mouth, constipation, urinary retention).
* **Dopamine Antagonists (e.g., Metoclopramide):** Antagonistic effects on GI motility; avoid concurrent use if aiming for prokinetic effect.
* **Antihistamines:** Potential for additive anticholinergic toxicity.
## Monitoring
* Monitor for symptom relief and bowel function.
* Assess for urinary retention, especially in elderly males with BPH.
* Monitor heart rate if administered IV.
## Clinical Pearls
* **Limited Absorption:** Oral bioavailability is very low (<10%). Parenteral routes are significantly more effective for acute, severe spasm.
* **Palliative Care:** It is a first-line agent for the management of excessive respiratory secretions due to antisialagogue effects.
* **Not a CNS agent:** It does not treat motion sickness (unlike scopolamine hydrobromide patches which cross the blood-brain barrier).
***
**Educational Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Always verify dosages, contraindications, and drug-drug interactions against current institutional protocols, local guidelines, and the manufacturer’s package insert before prescribing or administering medication.
